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ATM-Chk2 network is critical for genomic stability, and its deregulation may influence breast cancer pathogenesis. We
investigated ATM and Chk2 protein levels in two cohorts [cohort 1 (n = 1650) and cohort 2 (n = 252)]. ATM and Chk2
mRNA expression was evaluated in the Molecular Taxonomy of Breast Cancer International Consortium cohort (n =
1950). Lownuclear ATMprotein levelwas significantly associatedwith aggressive breast cancer including larger tumors,
higher tumor grade, highermitotic index, pleomorphism, tumor type, lymphovascular invasion, estrogen receptor (ER)−,
PR−, AR−, triple-negative, and basal-like phenotypes (Ps b .05). Breast cancer 1, early onset negative, low XRCC1, low
SMUG1, high FEN1, high MIB1, p53 mutants, lowMDM2, low Bcl-2, low p21, low Bax, high CDK1, and low Chk2 were
also more frequent in tumors with low nuclear ATM level (Ps b .05). Low ATM protein level was significantly associated
with poor survival including in patients with ER-negative tumors who received adjuvant anthracycline or cyclopho-
sphamide, methotrexate, and 5-fluorouracil–based adjuvant chemotherapy (Ps b .05). Low nuclear Chk2 protein was
likely in ER−/PR−/AR−; HER-2 positive; breast cancer 1, early onset negative; lowXRCC1; lowSMUG1; lowAPE1; low
polβ; lowDNA-PKcs; lowATM; lowBcl-2; and lowTOPO2A tumors (P b .05). In patientswith ER+ tumorswho received
endocrine therapy or ER-negative tumorswho received chemotherapy, nuclear Chk2 levels did not significantly influence
survival. In p53 mutant tumors, low ATM (P b .000001) or high Chk2 (P b .01) was associated with poor survival. When
investigated together, low-ATM/high-Chk2 tumors have the worst survival (P= .0033). Our data suggest that ATM-Chk2
levels in sporadic breast cancer may have prognostic and predictive significance.
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Ataxia–telegiectasia mutated (ATM), a member of the PI3K-like
protein kinases family of serine threonine kinases, is a key player in
the maintenance of genomic integrity [1–4]. ATM is activated and
recruited to sites of double-strand breaks through the Mre11–Rad50–
NBS1 complex. Activated ATM in turn phosphorylates a number of
proteins involved in cellular homeostasis [1–4]. A key substrate of
ATM is Chk2 whose phosphorylation at Thr68 results in activation
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breast cancer 1, early onset (BRCA1), and others [5–9]. Proficient
ATM-Chk2 signaling network is therefore essential for coordination
of DNA repair, cell cycle progression, and apoptosis in response to
DNA damage.
Accumulating evidence provides compelling evidence that germ-
line mutations in ATM[10–13] and Chk2[14] may result in a
predisposition to several tumors including hereditary breast cancers.
In addition, in sporadic tumors, emerging data also suggest a role for
ATM and Chk2 somatic mutations in cancer development [10–14].
However, whether such somatic mutations or deregulation of protein
expression has clinicopathological, prognostic, and predictive signif-
icance in sporadic breast cancer has not been clearly defined. In the
current study, we have comprehensively investigated ATM and Chk2
in large cohorts of early-stage breast cancers. The data presented here
suggest that impaired ATM-Chk2 pathway may influence the
development of aggressive phenotypes that are associated with poor
clinical outcomes in patients.
Patients and Methods
The Reporting Recommendations for Tumour Marker Prognostic
Studies criteria, recommended by McShane et al. [15], were followed
throughout this study. This work was approved by the Nottingham
Research Ethics Committee.
Cohort 1
This is a consecutive series of 1650 patients with primary invasive
breast carcinomas who were diagnosed between 1986 and 1999 and
entered into the Nottingham Tenovus Primary Breast Carcinoma
series. This is a well-characterized series of patients with long-term
follow-up that have been investigated in a wide range of biomarker
studies [16–21]. Supplementary Table S1 summarizes patient
demographics, and supplementary treatment data 1 summarizes the
various adjuvant treatment regimens received by patients in this group.
Cohort 2
An independent series of 252 estrogen receptor (ER)-α–negative
invasive breast cancers diagnosed and managed at the Nottingham
University Hospitals between 1999 and 2007 was also evaluated for
ATM and Chk2 expression. All patients were primarily treated with
surgery, followed by radiotherapy and anthracycline chemotherapy.
The characteristics of this cohort are summarized in Supplementary
Table S2.
Tissue Microarray (TMA) and Immunohistochemistry
TMAs were constructed and immunohistochemically profiled for
ATM, Chk2, and other biological antibodies. The optimization and
specificity of the antibodies used in the current study have been
described in previous publications [16–27] and listed in Supplemen-
tary Table S3. A set of slides was incubated for 18 hours at 4°C with
the primary mouse monoclonal anti-ATM antibody, clone Y170
(Ab32420, Abcam, Cambridge, UK), at a dilution of 1:100. A further
set of slides was incubated for 60 minutes with the primary rabbit
polyclonal anti-Chk2 antibody (Ab47433, Abcam, Cambridge, UK)
at a dilution of 1:100. To evaluate the use of TMAs for
immunophenotyping, full-face sections of 40 cases were stained and
protein expression levels of ATM and Chk2 were compared. The
concordance between TMAs and full-face sections was excellent (k =
0.8). Positive and negative (by omission of the primary antibody and
IgG-matched serum) controls were included in each run. Whole fieldinspection of the core was scored, and intensities of nuclear staining
were grouped as follows: 0 = no staining, 1 = weak staining, 2 =
moderate staining, 3 = strong staining. The percentage of each category
was estimated (0-100%). H-score (range 0-300) was calculated by
multiplying intensity of staining and percentage staining. X-tile (version
3.6.1; Yale University, New Haven, CT) was used to identify a cutoff
for ATM protein expression. The percentage of positive cells was used,
with a cut off of b25% cells being classed as low and ≥25% as high for
nuclear ATM protein level. For Chk2 nuclear expression level, H-score
cutoff was the median, and H-score of ≥100 was considered high for
nuclear Chk2 expression. Not all cores within the TMA were suitable
for immunohistochemistry analysis as some cores weremissing or lacked
tumor. Human epidermal growth factor receptor 2 (HER2) expression
was assessed according to the new American Society of Clinical
Oncology/The College of American Pathologists guidelines using
chromogenic in situ hybridization [28].
Statistical Analyses
Data analysis was performed using SPSS (SPSS, version 17,
Chicago, IL). Where appropriate, Pearson’s Chi-square, Fisher’s
exact, χ2 for trend, Student’s t and analyses of variance one-way tests
were performed using SPSS software (SPSS, version 17, Chicago, IL).
Cumulative survival probabilities were estimated using the Kaplan-
Meier method. Differences between survival rates were tested for
significance using the log-rank test. Multivariate analysis for survival
was performed using the Cox hazard model. The proportional hazards
assumption was tested using standard log-log plots. Each variable was
assessed in univariate analysis as a continuous and categorical variable,
and the two models were compared using an appropriate likelihood
ratio test. Hazard ratios and 95% confidence intervals (95% CI) were
estimated for each variable. All tests were two-sided with a 95% CI. P
values for each test were adjusted with Benjamini and Hochberg
multiple P value adjustment, and an adjusted P value of b .05 was
considered significant.
Molecular Taxonomy of Breast Cancer International Consortium
(METABRIC) Cohort for mRNA Expression
The mRNA expression was performed in the METABRIC cohort.
The METABRIC study protocol, detailing the molecular profiling
methodology in a cohort of 1980 breast cancer samples, is described
by Curtis et al. [29]. Patient demographics are summarized in
Supplementary Table S4 of supporting information. ER-positive and/
or lymph node–negative patients did not receive adjuvant chemo-
therapy. ER-negative and/or lymph node–positive patients received
adjuvant chemotherapy. RNA was extracted from fresh frozen tumors
and subjected to transcriptional profiling on the Illumina HT-12 v3
platform. The data were preprocessed and normalized as described
previously [29], and gene expression was investigated in this data set.
X-tile (version 3.6.1; Yale University, New Haven, CT) was used to
identify a cutoff in gene expression values to divide the population in
to high/low subgroups before analysis. Cumulative survival proba-
bilities were estimated using the Kaplan-Meier method.Breast Cancer Clines, Tissue Culture, and Western Blot Analysis
Supplementary Table S5 summarizes the molecular profile of breast
cancer cells evaluated for ATM and Chk2 protein levels. MCF-7 (ER+/
PR+/HER2−, BRCA1 proficient, PTEN proficient), MDA-MB-231
(ER−/PR−/HER2−, BRCA1 proficient, PTEN proficient), BT-549
(ER−/PR−/HER2−, BRCA1 proficient, PTEN deficient), MDA-
β-actin
Chk2
ATM
β-actin
ATM (whole cohort)
Log Rank = 14.26; p = 0.000015
High (n=567) 
Low (n=616) 
Chk2 (whole cohort)
Log Rank = 0.350; p = 0.554 
High (n=640)
Low (n=498)
A
B
C
D
0
0.0002
0.0004
0.0006
0.0008
0.001
0.0012
0.0014
0.0016
0.0018
Ch
k2
 p
ro
te
in
 
e
xp
re
ss
io
n
0
0.001
0.002
0.003
0.004
0.005
0.006
AT
M
 p
ro
te
in
 e
xp
re
ss
io
n
E
Negative ATM Chk2
Figure 1. (A) Western blot of ATM expression in breast cancer cell lines. (B) Western blot of Chk2 expression in breast cancer cell lines.
(C) Microphotograph of ATM and Chk2 negative and positive breast cancer tissue. (D) Kaplan-Meier curves showing BCSS and ATM
level. (E) Kaplan-Meier curves showing BCSS and Chk2 level.
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and MDA-MB-436 (ER−/PR−/HER2−, BRCA1 deficient, PTEN
deficient) were purchased from ATCC and were grown in RPMI
(MCF-7, MDA-MB-231) or Dulbecco’s modified Eagle’s medium
(BT-549, MDA-MB-468, and MDA-MB-436) with the addition of
10% fetal bovine serum and 1% penicillin/streptomycin. ATM-
deficient HeLa SilenciX® cells and control ATM proficient HeLa
SilenciX® cells were purchased from Tebu-Bio (www.tebu-bio.com).
SilenciX cells were grown in Dulbecco’s modified Eagle’s medium
(with L-glutamine 580 mg/l, 4500 mg/l D19 glucose, with 110 mg/l
sodium pyruvate) supplemented with 10% fetal bovine serum, 1%
penicillin/streptomycin, and 125 μg/ml Hygromycin B. Previously
well-characterized CH lung fibroblast cells; V79 (ATM wild type),
V-E5 (ATM deficient) were grown in Ham’s F-10 media (PAA, UK)
[supplemented with 10% fetal bovine serum (PAA,UK) and 1%
penicillin/streptomycin]. Cell lysates were prepared. and Western
blot analysis was performed. Primary antibodies were incubated
overnight at room temperature [Chk2 1:250 dilution, ATM 1:1500
and β-actin 1:10,000 dilution (Abcam)]. Infrared dye-labeled
secondary antibodies (Li-Cor) (IRDye 800CW Mouse Anti-Rabbit
IgG and IRDye 680CW Rabbit Anti-Mouse IgG) were incubated at
a dilution of 1:10,000 for 1 hour. Membranes were scanned with a
Li-Cor Odyssey machine (700 and 800 nm) to determine protein
expression. ATM or Chk2 expression was quantified after
normalizing with β-actin.Results
We initially profiled a panel of breast cancer cell lines for ATM and
Chk2 protein expression. A wide spectrum of expression of ATM was
evident across breast cancer cell lines (Figure 1A).MCF-7 has the lowest
expression, whereas MDA-MB-436 has the highest ATM expression.
MDA-MB-231, BT-549, and MDA-MB-468 exhibit reduced expres-
sion of ATM compared to MDA-MB-436. For Chk2 (Figure 1B),
MCF7 has the highest Chk2 expression compared to MDA-MB-231,
which has the lowest. BT-549, MDA-MB-436, and MDA-MB-468
have lowChk2 expression compared toMCF-7 cells. Together, the data
reveal differential expression of ATM and Chk2 proteins in different
breast cancer cell lines. To further evaluate the specificity of ATM
antibody used in the current study, we performed Western blots in cell
lysates from Chinese hamster lung fibroblasts [ATM deficient (V-E5
cells) and ATM proficient (V-79 cells)] and HeLa cells [ATM-deficient
SilenciX cells where ATM has been knocked down by stable shRNA
and ATM proficient control cells]. As shown in Supplementary Figure
S1, ATM-proficient cells have robust ATM expression, and in ATM-
deficient cells, there is no/minimal ATM expression. We then
conducted immunohistochemical investigation of ATM and Chk2
expression in human breast tumor samples.
ATM Levels and Breast Cancer
A total of 1183 tumors were suitable for ATM analysis. High
nuclear ATM level was seen in 567/1183 (48%) tumors compared to
Table 1. ATM Protein Level in Sporadic Breast Cancer
Variable ATM Protein Expression P Value
Low N (%) High N (%)
A) Pathological parameters
Tumor size
.027b1 cm 87 (14.1) 76 (13.4)
N1-2 cm 295 (47.9) 319 (56.3)
N2-5 cm 218 (35.4) 161 (28.4)
N5 cm 16 (2.6) 11 (1.9)
Tumor stage
.2731 399 (63.2) 386 (67.5)
2 179 (28.4) 147 (25.7)
3 53 (8.4) 39 (6.8)
Tumor grade*
1.0 × 10−6G1 75 (12.2) 142 (25.0)
G2 202 (32.8) 190 (33.5)
G3 339 (55.0) 235 (41.4)
Mitotic index
3.0 × 10−6M1 (low; mitoses b 10) 190 (30.9) 253 (44.6)
M2 (medium; mitoses 10-18) 116 (18.9) 100 (17.6)
M3 (high; mitosis N18) 308 (50.2) 214 (37.7)
Tubule formation
1.1 × 10−51 (N75% of definite tubule) 37 (6.0) 42 (7.4)
2 (10%-75% definite tubule) 166 (27.0) 222 (39.2)
3 (b10% definite tubule) 411 (66.9) 303 (53.4)
Pleomorphism
2.4 × 10−51 (small-regular uniform) 15 (2.4) 26 (4.6)
2 (moderate variation) 213 (34.7) 258 (45.5)
3 (marked variation) 386 (62.9) 283 (49.9)
Tumor type
1.0 × 10−4IDC-NST 337 (64.7) 271 (53.7)
Tubular carcinoma 79 (15.2) 133 (26.3)
Medullary carcinoma 20 (3.8) 11 (2.2)
ILC 48 (9.2) 50 (9.9)
Others 37 (7.1) 40 (7.9)
Lymphovascular invasion
.001No 388 (65.2) 417 (74.5)
Yes 207 (34.8) 143 (25.5)
B) Aggressive phenotype
Her2 overexpression
.389No 506 (87.5) 487 (89.2)
Yes 72 (12.5) 59 (10.8)
Triple-negative phenotype
2.2x10−4No 459 (76.8) 476 (85.3)
Yes 139 (23.2) 82 (14.7)
Basal-like phenotype
.046No 494 (85.0) 487 (89.0)
Yes 87 (15.0) 60 (11.0)
CK6
.301Negative 424 (83.3) 404 (80.8)
Positive 87 (16.7) 96 (19.2)
CK14
.062Negative 451 (88.8) 424 (84.8)
Positive 87 (11.2) 76 (15.2)
CK18
1.1 × 10−4Negative 73 (14.6) 31 (6.8)
Positive 428 (85.4) 424 (93.2)
CK19
1.2 × 10−4Negative 46 (9.0) 16 (3.2)
Positive 463 (91.0) 480 (96.8)
C) Hormone receptors
ER
1.9 × 10−5Negative 207 (33.4) 126 (22.3)
Positive 412 (66.6) 440 (77.7)
PgR
7.5 × 10−5Negative 271 (48.1) 190 (36.3)
Positive 292 (51.9) 334 (63.7)
AR
4.6 × 10−5Negative 212 (43.5) 144 (30.8)
Positive 275 (56.5) 324 (69.2)
D) DNA repair
BRCA1
3.0 × 10−6Absent 110 (24.8) 50 (12.3)
Normal 333 (75.2) 358 (87.7)
(continued on next page)
TABLE 1 (continued)
Variable ATM Protein Expression P Value
Low N (%) High N (%)
XRCC1
.002Low 81 (19.4) 43 (11.4)
High 336 (80.6) 334 (88.6)
FEN1
.018Low 301 (75.8) 241 (68.1)
High 96 (24.2) 113 (31.9)
SMUG1
2.0 × 10−6Low 173 (47.1) 97 (29.4)
High 194 (52.9) 233 (70.6)
APE1
.152Low 215 (52.7) 173 (47.5)
High 193 (47.3) 191 (52.5)
PolB
.607Low 178 (40.1) 148 (38.3)
High 266 (59.5) 238 (61.7)
DNA-PKcs
.946Low 138 (35.9) 116 (35.7)
High 246 (64.1) 209 (64.3)
E) Cell cycle/apoptosis regulators
P16
.151Low 358 (83.4) 354 (87.0)
High 71 (16.6) 53 (13.0)
P21
.002Low 274 (63.7) 235 (53.5)
High 156 (36.3) 204 (46.5)
MIB1
.001Low 222 (44.7) 266 (55.8)
High 275 (55.3) 211 (44.2)
P53
.034Low expression 379 (56.7) 393 (82.2)
High expression 115 (23.3) 85 (17.8)
Bcl-2
.002Negative 209 (39.6) 153 (30.4)
Positive 319 (60.4) 351 (69.6)
TOP2A
.238Low 195 (46.9) 161 (42.7)
Overexpression 221 (53.1) 216 (57.3)
CHK2
.009Low 329 (92.2) 255 (85.9)
High 28 (7.8) 42 (14.1)
Bax
.010Low 252 (72.2) 189 (62.8)
High 97 (27.8) 111 (37.2)
CDK1
.009Low 204 (65.8) 200 (75.8)
High 106 (34.2) 64 (24.2)
MDM2
1.0 × 10−6Low 353 (81.3) 280 (63.3)
Overexpression 81 (18.7) 162 (36.7)
Bold = statistically significant; PgR: progesterone receptor; CK: cytokeratin; Basal-like: ER−, HER2,
and positive expression of either CK5/6, CK14, or EGFR; Triple negative: ER−/PgR−/HER2−.
* Grade as defined by Nottingham Grading System.
TABLE 1 (continued)
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(Table 1). Low nuclear ATM level was associated with larger tumors
(P = .027), higher tumor grade (P b .001), higher mitotic index (P b
.001), pleomorphism (P b .001), tumor type (P b .001), and
lymphovascular invasion (P = .001) (Table 1). Triple-negative (P b
.001) and basal-like phenotype (P = .046) breast cancers were more
commonly low nuclear ATM tumors. ER−, PR−, and AR− were also
more common in low–nuclear ATM tumors (P b .001). BRCA1
negative, low XRCC1, low SMUG1, and low FEN1 were also more
likely associated with low ATM level in tumors (P b .05). In addition,
high MIB1, p53 mutants, low MDM2, Bcl-2 mutants, low p21, low
Bax, high CDK1, and low Chk2 were likely in tumors with low
nuclear ATM levels (P b .05).
p53-/ATM+ (n=424)
p53+/ATM- (n=231)
p53-/ATM- (n=435)
p53+/ATM+ (n=157)
Log Rank = 48.561; p = 0.0000001
ATM and p53 combined 
Log Rank = 13.39; p = 0.004 
p53-/Chk2+ (n=88)
p53+/Chk2+ (n=104)
p53-/Chk2- (n=320)
p53+/Chk2- (n=372)
Chk2 and p53 combined
Log Rank = 8.706; p = 0.033 
Chk2-/ATM- (n=184)
Chk2+/ATM- (n=167)
Chk2-/ATM+ (n=130)
Chk2+/ATM+ (n=166)
ATM-Chk2 co-expression
A B
C
Figure 2. (A) Kaplan-Meier curves showing BCSS stratified based on p53 mutation status and ATM level. (B) Kaplan-Meier curves
showing BCSS stratified based on p53 mutation status and Chk2 level. (C) Kaplan-Meier curves showing BCSS stratified based on ATM
and Chk2 coexpression.
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survival (BCSS) in patients (P b .0001) (Figure 1D). As ATM
mediated activation and stabilization of p53 are essential for genomic
stability and cell cycle response, we conducted exploratory analysis in
p53 mutant and proficient tumors. p53 mutants with low ATM levels
have the worst survival compared to p53 wild-type tumors with high
ATM levels (P b .0001) (Figure 2A). Tumors that are p53 mutants
with high ATM levels and p53 wild type with low ATM levels have
intermediate prognosis. We then investigated in ER+ and ER−
subgroups. ER+ tumors were from cohort 1. For ER-negative tumors,
we combined tumors from cohort 1 and cohort 2 for the subgroup
analysis. In high-risk (NPI N 3.4) ER-negative tumors that received
no adjuvant chemotherapy, low ATM was associated with poor
survival (P = .041) (Supplementary Figure S2A). In high-risk
ER-negative tumors that received anthracycline (Figure 3A) or
cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) adjuvant
chemotherapy (Figure 3B), low ATM remains associated with poor
survival (P = .030 and P = .021, respectively). In ER+ tumors, ATM
level did not significantly influence clinical outcomes (Figure 2C and
Supplementary Figure S2B). At the mRNA level, low ATM was seenin 10% of tumors (202/1977). Although there was a trend, low ATM
expression was not significantly associated with poor BCSS in the
whole cohort (P = .080, Figure 3D) and in the ER− cohort that
received chemotherapy (P = .065, Figure 3E). Interestingly, low ATM
expression was significantly associated with poor BCSS in the ER+
cohort that received endocrine therapy (P = .020, Figure 3F).
Chk2 Levels and Breast Cancer
A total of 1138 tumors were suitable for Chk2 analysis. High
nuclear Chk2 level was seen in 640/1138 (56%) tumors compared to
498/1138 (44%) tumors that had low nuclear Chk2 level (Figure 1C)
(Table 2). Low nuclear Chk2 was likely in HER-2–overexpressing
tumors. ER−/PR−/AR− tumors were also more likely in tumors with
low nuclear Chk2 levels. BRCA1 negative, XRCC1 low, FEN1 low,
SMUG1 low, APE1 low, polβ low, DNA-PKcs low, ATM low, Bcl-2
low, TOPO2A low, and MDM2 low tumors were more likely in
tumors with low nuclear Chk2 levels (P b .05) (Table 2). In the whole
cohort, there was no significant association with BCSS (Figure 1E).
However, when stratified based on p53 mutation status, p53 mutants
with high nuclear Chk2 appear to have poor outcome compared to
ATM (ER-,NPI>3.4,Anthracyclin chemotherapy)
High (n=64) 
Low (n=84) 
Log Rank = 4.684; p = 0.030 
High (n=134) 
Low (n=265) 
Log Rank = 5.342; p = 0.021 
ATM (ER-,NPI>3.4,CMF chemotherapy)
High (n=150) 
Low (n=168) 
Log Rank = 3.340; p = 0.068
ATM (ER+,NPI>3.4,endocrine therapy)
ATM mRNA (whole cohort) 
High ATM mRNA (n=1775)
Low ATM mRNA (n=202)
Log Rank = 3.068; P = 0.080
ATM mRNA (ER+ , endocrine therapy)
High ATM mRNA (n=903)
Low ATM mRNA (n=200)
Log Rank = 5.405; P = 0.020 
ATM mRNA, (ER- chemotherapy)
High ATM mRNA (n=230)
Log Rank = 3.418; P = 0.065 
Low ATM mRNA (n=42)
A B
D E F
C
Figure 3. (A) Kaplan-Meier curves showing BCSS based on ATM levels in ER− patients who received anthracycline chemotherapy.
(B) Kaplan-Meier curves showing BCSS based on ATM levels in ER− patients who received CMF chemotherapy. (C) Kaplan-Meier
curves showing BCSS based on ATM levels in ER+ patients who received endocrine therapy. (D) Kaplan-Meier curves showing BCSS
based on ATMmRNA expression in the whole cohort. (E) Kaplan-Meier curves showing BCSS based on ATMmRNA expression in ER−
patients who received chemotherapy. (F) Kaplan-Meier curves showing BCSS based on ATM mRNA expression in ER+ patients who
received endocrine therapy.
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also performed subgroup analysis based on ER status in tumors. In
ER− tumors that received no adjuvant chemotherapy, high nuclear
Chk2 was associated with poor survival (P = .047) (Supplementary
Figure S2C). However, in ER+ tumors that received no adjuvant
endocrine therapy, low nuclear Chk2 was associated with poor survival
(P = .014) (Supplementary Figure S2D). In patients with ER+ tumors
who received endocrine therapy or ER-negative tumors who received
chemotherapy, nuclear Chk2 levels did not significantly influence
clinical outcome (Figure 4A, B, and C). At the mRNA level, high Chk2
expression was significantly associated with poor BCSS in the whole
cohort (P b .001, Figure 4D) and in the ER+ cohort that received
endocrine therapy (P = .006, Figure 4F). However, low Chk2
expression was significantly associated with poor BCSS in the ER−
cohort that received chemotherapy (P = .020, Figure 4E).
ATM-Chk2 Coexpression in Breast Cancer
As there was a strong positive association between ATM and Chk2
expression (see Table 1 and Table 2), we investigated if coexpression
would influence survival. Patients with tumors that have low ATM
and high Chk2 levels have the worst survival compared to tumors
that have high ATM and high Chk2 levels (P = .033) (Figure 2C).
The data suggest that ATM and Chk2 together have prognostic
significance in patients. We then investigated in patients who
received chemotherapy or endocrine therapy. As shown in
Supplementary Figure S3, although there was trend, ATM-Chk2expression did not significantly influence survival in patients in the
various subgroups.
Multivariate Analysis
To investigate whether ATM-Chk2 independently influenced
survival, we proceeded to multivariate analysis. As shown in Table 3,
in multivariate Cox regression analysis including other validated
prognostic factors (such as stage, histological grade, tumor size, p53,
MIB1, and bcl-2), Chk2 expression was an independent predictor for
BCSS. ATM-Chk2 coexpression showed a trend and reached near
significance (P = .056).
Taken together, the data provide evidence that ATM and Chk2
expression has prognostic and predictive significance in breast cancer.
Discussion
This is the largest study to investigate the clinicopathological
significance of ATM-Chk2 expression in sporadic breast cancers. A
low level of ATM was associated with aggressive phenotypes
including high grade, high mitotic index, pleomorphisms, de-
differentiation, and triple-negative and basal-like phenotypes. The
association between ER negativity and low ATM in human tumors
concurs with the breast cancer cell line data where ATM was found to
be low in several triple-negative cell lines including MDA-MB-231,
BT-549, and MDA-MB-468 cells. ATM is a key player in the
maintenance of genomic integrity [1–4]. Loss of ATM and the
resulting genomic instability may promote a mutator phenotype
Table 2. Chk2 Protein Level in Sporadic Breast Cancers
Variable Chk2 Protein Expression P Value
Low N (%) High N (%)
A) Pathological parameters
Tumor size .483
b1 cm 43 (8.6) 111 (10.1)
N1-2 cm 250 (50.2) 290 (48.3)
N2-5 cm 190 (38.2) 224 (37.5)
N5 cm 15 (3.0) 15 (2.5)
Tumor stage .441
1 302 (60.4) 383 (64.2)
2 151 (30.2) 163 (27.3)
3 47 (9.4) 51 (8.5)
Tumor grade* .144
G2 140 (28.1) 192 (32.2)
G3 294 (59.0) 317 (53.1)
Mitotic index .241
M1 (low; mitoses b 10) 144 (29.0) 188 (31.6)
M2 (medium; mitoses 10-18) 88 (17.7) 120 (20.2)
M3 (high; mitosis N18) 264 (53.2) 286 (48.1)
Tubule formation .912
1 (N75% of definite tubule) 21 (4.2) 23 (3.9)
2 (10%-75% definite tubule) 153 (30.8) 189 (31.8)
3 (b10% definite tubule) 322 (64.9) 382 (64.3)
Pleomorphism .070
1 (small-regular uniform) 11 (2.2) 12 (2.0)
2 (moderate variation) 151 (30.4) 220 (37.1)
3 (marked variation) 334 (67.3) 361 (60.9)
Tumor type .235
IDC-NST 274 (62.7) 325 (63.5)
Tubular carcinoma 77 (17.6) 90 (17.6)
Medullary carcinoma 18 (4.1) 9 (1.8)
ILC 30 (6.9) 44 (8.6)
Others 38 (8.7) 44 (8.6)
Lymphovascular invasion .282
No 315 (64.3) 397 (67.4)
Yes 175 (35.7) 192 (32.6)
B) Aggressive phenotype
Her2 overexpression .017
No 410 (84.2) 518 (89.2)
Yes 77 (15.8) 63 (10.8)
Triple-negative phenotype .140
No 379 (78.0) 475 (81.6)
Yes 107 (22.0) 107 (18.4)
Basal-like phenotype .410
No 400 (85.5) 492 (87.2)
Yes 68 (14.5) 72 (12.8)
CK6 .970
Negative 353 (83.1) 414 (83.0)
Positive 72 (16.9) 85 (17.0)
CK14 .566
Negative 368 (86.6) 434 (87.9)
Positive 57 (13.4) 60 (12.1)
CK18 .271
Negative 49 (12.3) 46 (10.0)
Positive 348 (87.7) 415 (90.0)
CK19 .478
Negative 28 (6.7) 39 (7.9)
Positive 392 (93.3) 455 (92.1)
C) Hormone receptors
ER .008
Negative 163 (33.1) 151 (25.7)
Positive 330 (66.9) 437 (74.3)
PgR .006
Negative 232 (49.3) 225 (40.7)
Positive 239 (50.7) 328 (59.3)
AR .002
Negative 181 (45.5) 165 (35.0)
Positive 217 (54.5) 306 (65.0)
D) DNA repair
BRCA1 2.1 × 10−4
Absent 101 (27.7) 69 (16.7)
Normal 263 (72.3) 343 (83.3)
TABLE 2 (continued)
Variable Chk2 Protein Expression P Value
Low N (%) High N (%)
XRCC1 2.2 × 10−4
Low 86 (22.9) 54 (12.9)
High 289 (77.1) 364 (87.1)
FEN1 2.1 × 10−4
Low 287 (81.3) 272 (69.6)
High 147 (18.7) 119 (30.4)
SMUG1 .003
Low 155 (46.8) 131 (35.6)
High 176 (53.2) 237 (64.4)
APE1 1.0 × 10−6
Low 320 (68.7) 220 (38.9)
High 146 (31.3) 346 (61.1)
PolB 1.0 × 10−6
Low 226 (48.9) 173 (30.8)
High 236 (51.5) 388 (69.2)
ATM .026
Low 188 (59.1) 170 (50.4)
High 130 (40.9) 167 (49.6)
DNA-PKcs 1.0 × 10−6
Low 187 (45.2) 134 (29.5)
High 226 (54.7) 321 (70.5)
E) Cell cycle/apoptosis regulators
P16 .187
Low 294 (83.1) 352 (86.5)
High 60 (16.9) 55 (13.5)
P21 .192
Low 227 (61.5) 238 (56.9)
High 142 (38.5) 180 (43.1)
MIB1 .405
Low 164 (40.6) 218 (43.3)
High 240 (59.4) 285 (56.7)
P53 0.856
Low expression 322 (78.5) 373 (78.0)
High expression 88 (21.5) 105 (22.0)
Bcl-2 .002
Negative 194 (43.3) 176 (33.6)
Positive 254 (56.7) 348 (66.4)
TOP2A 1.8 × 10−5
Low 195 (53.7) 166 (38.5)
Overexpression 168 (46.3) 265 (61.5)
Bax .435
Low 200 (69.7) 248 (72.5)
High 87 (30.3) 94 (27.5)
CDK1 .547
Low 278 (69.8) 292 (67.9)
High 120 (30.2) 138 (32.1)
MDM2 .001
Low 279 (90.6) 299 (81.7)
Overexpression 29 (9.4) 67 (18.3)
Bold = statistically significant.
* Grade as defined by Nottingham Grading System.
TABLE 2 (continued)
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ultimately drive an aggressive cancerous phenotype. Herein we
demonstrate that, at the protein level, low ATM expression was
associated with high grade, high mitotic index, de-differentiation, and
pleomorphism. The hypothesis that low ATM is associated with
genomic instability is further supported by the observation that low
ATM was significantly associated with low expression of other DNA
repair factors including BRCA1, XRCC1, FEN1, and SMUG1.
Moreover, as low ATM tumors were also more likely to be p53
mutants, we speculate that this could contribute to additional
genomic instability in tumors. In addition, not only was low ATM
level significantly associated with mutant p53 status, but low-ATM/
p53 mutants also have the worst survival compared to p53 wild-type/
high-ATM tumors. The data suggest that ATM/p53-based stratifi-
cation could be useful for personalization of therapy. A previous small
study in 93 breast cancers suggested that tumors with normal ATM
High Chk2 (n=60) 
Low Chk2 (n=102) 
Log Rank = 2.039; p = 0.153 
Chk2 (ER-,NPI>3.4,Anthracyclin chemotherapy)
Low Chk2 (n=53) 
High Chk2 (n=46) 
Log Rank = 0.061; p = 0.805 
Chk2 (ER-,NPI>3.4,CMF chemotherapy)
High Chk2 (n=182) 
Low Chk2 (n=141) 
Log Rank = 0.243; p = 0.622 
Chk2 (ER+,NPI>3.4, endocrine therapy)
Chk2 mRNA expression (whole cohort) 
Low CHK2 (n=1205)
High CHK2 (n=772)
Log Rank = 14.09; p = 0.000017
CHK2 mRNA, (ER-chemotherapy)
High CHK2 mRNA (n=191) 
Low CHK2 mRNA (n=81) 
Log Rank = 5.405; p = 0.020
CHK2mRNA, ER+ , endocrine therapy) 
High CHK2 mRNA (n=934)
Low CHK2 mRNA (n=169)
Log Rank = 7.515; p = 0.006
A B
D E F
C
Figure 4. (A) Kaplan-Meier curves showing BCSS based on Chk2 levels in ER− patients who received anthracycline chemotherapy.
(B) Kaplan-Meier curves showing BCSS based on Chk2levels in ER− patients who received CMF chemotherapy. (C) Kaplan-Meier
curves showing BCSS based on Chk2 levels in ER+ patients who received endocrine therapy. (D) Kaplan-Meier curves showing BCSS
based on Chk2mRNA expression in the whole cohort. (E) Kaplan-Meier curves showing BCSS based on Chk2mRNA expression in ER−
patients who received chemotherapy. (F) Kaplan-Meier curves showing BCSS based on Chk2 mRNA expression in ER+ patients who
received endocrine therapy.
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ATM and wild-type p53 have poor survival [30]. The authors
described only four tumors that had both low ATM and aberrant
p53, and this was associated with good survival in that study [30]. In
contrast, in our study, 231 tumors were p53 mutants with low ATM,
and such tumors exhibited poor survival. Interestingly, in patients
who received either anthracycline-based or CMF adjuvant chemo-
therapy, low ATM level was associated with poor survival, implying
that ATM may also predict response to chemotherapy. The data
appear to be counterintuitive in that several preclinical studies have
suggested that ATM-deficient cells are sensitive to cytotoxic
chemotherapy and radiotherapy [1–4]. However, our data would
concur with a recent report in breast cancers that showed a poor
survival in patients with low ATM who received adjuvant/
neoadjuvant chemotherapy [31]. Similarly, Knappskog et al., also
showed that low ATM predicts resistance to anthracycline chemo-
therapy in breast cancer [32]. To investigate whether low ATM
expression is due to low mRNA expression, we investigated the
METABRIC cohort and again demonstrated that low ATM mRNA
expression was associated with adverse clinical outcome in patients.
Whether ATM gene copy number changes, mutational changes, or
posttranscriptional miRNA-mediated regulation of ATM mRNA
expression contributes to the low ATM seen in our study is not
known. Interestingly, Bueno et al., demonstrated that ATM copy
number loss (seen in 12% of breast tumors) and miR-421
overexpression (seen in 36.5% of breast tumors) were associatedwith ATM loss, thereby providing some mechanistic evidence for
ATM regulation [31]. In contrast, Guo et al., who investigated 296
breast tumors in Chinese patients [33] observed high ATM levels in
ER− tumors. However, the authors did not describe any association
between ATM level and BCSS in that study. However, two previous
studies in white patients demonstrate that low ATM level may be
associated with aggressive phenotype and poor survival [31,34].
Tommiska et al., investigated in observed that low ATM was
common in BRCA1/BRCA2 deficient tumors as well as ER- tumors
[34]. In a further study in white patients by Bueno et al., low ATM in
white tumors was shown to be associated with poor prognosis [31].
Similarly, in the current study, in white patients with breast tumors,
we observed that low ATM protein level was associated with
aggressive clinicopathological features and poor survival in ER−
tumors. Taken together, the data suggest that, in white patients, low
ATM appears to be a poor prognostic biomarker. The data presented
in white tumors is in contrast to Guo et al. [33], and may be
accounted by either racial differences in tumor biology or different
immunohistochemical protocols used across different studies.
Preclinically, Guo et al., showed that ER activates miR-18a and
miR-106a, which in turn downregulate ATM in cancer cell lines as
well as in ER− tumors [33]. In contrast, Bueno et al., observed that
miR-421 was overexpressed and correlated to low ATM levels [31].
Together, the data suggest that the regulation of ATM expression by
miRNAs may be complex in vivo. Further mechanistic studies are
required to clarify the role of miRNA in the regulation of ATM
Table 3. Multivariate Analysis
P Value Exp (B)
95% CI of Exp (B)
Lower Upper
BCSS
Stage .001 1.810 1.413 2.320
Grade .065 1.402 0.979 2.009
Size .009 1.250 1.057 1.478
ATM .307 1.226 0.829 1.812
Chk2 .030 1.465 1.037 2.069
ATM-CHK2 coexpression .056 0.847 0.715 1.004
p53 .559 1.130 0.750 1.705
Bcl-2 .001 0.443 0.301 0.653
ER .371 1.221 0.788 1.893
Her2 .399 1.099 0.883 1.362
MIB1 .340 1.106 0.899 1.361
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studies in colorectal cancer [35] and chronic lymphocytic leukemia
[36] where low ATM level has been shown to be a poor prognostic
biomarker. Taken together, the data provide compelling evidence for
the role of low ATM expression in promoting aggressive breast
cancer. Whether such ATM-deficient tumors can be targeted by
synthetic lethality approaches has been investigated recently.
In lymphoid tumors, PARP inhibition was synthetically lethal in
ATM-deficient cells [37]. Similarly, in breast and gastric cancer cell
line, models of synthetic lethality with PARP inhibition have been
demonstrated [38,39]. Using a similar approach, we have recently
demonstrated that ATM-deficient cells are sensitive to inhibitors of
APE1, a key player in base excision repair [40]. Given the recent
clinical success of PARP inhibitors in BRCA1/2-deficient breast and
ovarian cancers [41], whether a similar clinical approach would be
feasible in ATM-deficient breast cancer clearly needs investigation in
prospective clinical trials. The role of Chk2 in sporadic breast cancer
appears to be more complex than ATM. In the current study, low
nuclear Chk2 protein level was associated with ER−/PR−/AR−
tumors. Moreover, low nuclear Chk2 level was also associated with
low levels of several DNA repair factors including BRCA1, XRCC1,
and APE1, implying increased genomic instability in tumors that
have low nuclear Chk2. In a previous small study of 100 breast
cancers, low Chk2 was reported to be associated with advanced stage
but not with survival [42]. Similarly, in another study of 611 breast
cancers [43], low Chk2 was reported in 21.1% of tumors and was
associated with larger tumor size but again not associated with
survival. In the current study, although we did not observe any
correlation with stage, in ER+ tumors that received no endocrine
therapy, low Chk2 was associated with poor survival, suggesting that
Chk2 may still have prognostic significance in ER+ tumors.
However, high Chk2 level was associated with poor survival in
ER-negative tumors that received no chemotherapy in our study.
Interestingly, p53 mutation status may influence the prognostic
impact of Chk2; p53 mutants with high Chk2 have the worst
survival, and p53 mutants with low Chk2 appear to have the best
survival. Given that Chk2 is a key activator of p53 [44] and that
combined inactivation of p53 and Chk2 has been reported in breast
cancers [45], detailed mechanistic preclinical investigations are
required to understand the complex functional link between Chk2
and p53 in breast tumors. Although Chk2 appeared to have
prognostic significance, Chk2 protein level was not associated with
survival in patients who received chemotherapy or endocrine therapy,suggesting that Chk2 is unlikely to be a predictive factor in breast
cancers. To complicate thematter further, we observed the reverse at the
mRNA level in breast tumors. Low Chk2 mRNA was associated with
poor survival in ER-negative tumors that received chemotherapy, but
high Chk2 mRNA was associated with poor survival in ER+ tumors
that received endocrine therapy. These new unexplained observations
suggest that further studies are required to clarify the role of Chk2 in
sporadic breast cancers. When ATM and Chk2 were investigated
together, we found that tumors with low ATM/high Chk2 had the
worst survival compared to those with high ATM/high Chk2 levels.
However, limitations to our study are that it was retrospective and
did not investigate the functional status of ATM-Chk2 pathway as
assessed, for example, by expression of phosphorylated Chk2 and
other ATM substrates.
In conclusion, we provide evidence that ATM-Chk2 pathway is a
promising biomarker in breast cancer.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.09.009.References
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